Skip to main content

Table 4 Effect of each parameter on OS according to baseline values and to the variation between T1 value (after 1 month of therapy) and T0 value (baseline value). This difference has been indicated as delta value (Δ)

From: Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma

Parameter

Univariate

Two-variable

Multivariablea

Variable

Timepoint

Value

p

HR

Lower HR

Upper HR

p

HR

Lower HR

Upper HR

p

HR

Lower HR

Upper HR

Platelets

Basal

 + 10,000

    

0.041

1.020

1.001

1.039

Δ

Ref ≤ 25,000

    

0.022

1.512

1.063

2.151

White blood cell count

Basal

 + 100

    

 < 0.001

1.009

1.005

1.013

Δ

Ref ≤ 1920

    

 < 0.001

3.246

2.171

4.854

 < 0.001

2.918

1.882

4.526

Neutrophils

Basal

 + 100

    

 < 0.001

1.014

1.010

1.018

 < 0.001

1.011

1.005

1.016

Δ

Ref ≤ 310

    

 < 0.001

1.880

1.330

2.659

Lymphocytes

Basal

 + 100

    

0.045

0.977

0.955

0.999

Δ

Ref ≥ -300

    

 < 0.001

2.319

1.578

3.409

0.038

1.627

1.028

2.576

NL ratio

Basal

 + 1

    

 < 0.001

1.279

1.169

1.400

Δ

Ref ≤ 0.86

    

 < 0.001

2.908

2.012

4.202

PL ratio

Basal

 + 1

    

0.006

1.003

1.001

1.005

0.022

1.003

1.000

1.005

Δ

Ref ≤ 22.85

    

 < 0.001

2.019

1.429

2.853

0.140

1.378

0.901

2.109

Age

Basal

 + 1

0.255

1.008

0.994

1.021

    

Sex

Basal

Ref F

0.282

0.829

0.589

1.166

    

Number of metastatic sites

Basal

Ref ≥ 3

0.089

0.746

0.532

1.046

    

LDH

Basal

Ref elevated

 < 0.001

0.395

0.276

0.564

    

 < 0.001

0.499

0.344

0.724

  1. Statistically significant values in bold
  2. At the Δ timepoint the variables have been dichotomized and the “value” represents the reference category
  3. HR (hazard ratio) values are expressed in terms of risk of mortality
  4. aAfter stepwise selection